artificial antigen presenting cell (AAPC)-expanded gamma delta T-cell therapy / H. Lee Moffitt Cancer Center and Research Institute - LARVOL DELTA

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | N=32 ➔ 20 | Trial completion date: Jun 2025 ➔ Sep 2026 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation